GlassScriptPhysician profile
Rita D Zuber
NPI 1720038003
$9,001.75
in general payments reported to CMS, 2019-2025
38 companies · $2,209 in 2025
The $2,209 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,769 · 2022: $1,950 · 2023: $1,249 · 2024: $1,825 · 2025: $2,209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,189 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,188.80 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,597.17 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,226.15 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $912.05 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $861.76 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Esperion Therapeutics, INC. | $534.15 | 2021-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $422.00 | 2022-2025 | |
| Amgen INC. | $396.93 | 2021-2025 | Otezla, Repatha, Repatha |
| Teva Pharmaceuticals USA, INC. | $361.48 | 2021-2025 | Ajovy |
| Abbott Laboratories | $269.79 | 2021-2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $254.65 | 2024-2025 | Rexulti, Nuedexta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.48 | 2021-2025 | Ofev, Jardiance, Synjardy |
| Pfizer INC. | $245.03 | 2023-2025 | |
| Glaxosmithkline, LLC. | $191.43 | 2022-2025 | Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $190.92 | 2021-2024 | Trintellix |
| Axsome Therapeutics, INC. | $166.49 | 2025 | Auvelity |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rita Zuber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.